<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9412">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00753675</url>
  </required_header>
  <id_info>
    <org_study_id>D4200L00007</org_study_id>
    <secondary_id>EUDRACT n° 2007-003056-12</secondary_id>
    <nct_id>NCT00753675</nct_id>
  </id_info>
  <brief_title>Vandetanib Gemcitabine Or Placebo Plus Gemcitabine Or Vandetanib Monotherapy In Advanced Biliary Tract Cancer</brief_title>
  <acronym>VANGOGH</acronym>
  <official_title>A Randomized, Multicentre, Phase II, Parallel-Group Trial of Vandetanib Monotherapy or Vandetanib in Combination With Gemcitabine Versus Gemcitabine Plus Vandetanib Matching Placebo in Subjects With Advanced Biliary Tract Cancer (Gallbladder Cancer, Cancer of the Extrahepatic Bile Duct, Intrahepatic Cholangiocarcinoma and Ampullary Carcinoma)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <authority>Italy: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the trial is to determine the efficacy of VANDETANIB monotherapy or
      VANDETANIB plus GEMCITABINE or PLACEBO plus GEMCITABINE in prolonging the progression-free
      survival (PFS) at the trial closure in patients with advanced (unresectable or metastatic)
      biliary tract cancer.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>up to 1032 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>PFS is calculated from the date of first dose of study medication until the date of objective progression or death (by any cause in the absence of progression). Patients who have not progressed or died at the time of statistical analysis will be censored at the time of their latest objective tumor assessment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Tumor Response Rate (CR+PR),</measure>
    <time_frame>up to 1032 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>ORR is the sum of patients with best overall complete or partial responses divided by the patients in the analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (CR+PR+SD)</measure>
    <time_frame>up to 1032 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>DCR is the sum of patients with a best overall CR, PR or SD (&gt;=8 weeks) by the patient in the analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>up to 1032 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>DOR is defined from the date of first documentation of response until date of PD or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survivall</measure>
    <time_frame>up to 1032 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>OS is defined from the date of randomization to death</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">174</enrollment>
  <condition>Biliary Tract Cancer</condition>
  <condition>Gallbladder Cancer</condition>
  <condition>Cancer Of The Extrahepatic Bile Duct</condition>
  <condition>Ampullary Carcinoma</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vandetanib 300 mg as a once daily oral dose, from Day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gemcitabine administered intravenously at 1000 mg/m2 over 30 minutes on Days 1 and 8 of each 21-day cycle up to plus Vandetanib 100 mg orally once-daily, from Day 1 (after 6 cycles, in the absence of disease progression or unacceptable toxicity, Investigators remain at liberty to continue Gemcitabine plus Vandetanib / Placebo or to continue Vandetanib / Placebo monotherapy)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Gemcitabine administered intravenously at 1000 mg/m2 over 30 minutes on Days 1 and 8 of each 21-day cycle up to 6 cycles plus Vandetanib 100 mg Matching Placebo orally once-daily, from Day 1 (after 6 cycles, in the absence of disease progression or unacceptable toxicity, Investigators remain at liberty to continue Gemcitabine plus Vandetanib / Placebo or to continue Vandetanib / Placebo monotherapy).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZD6474, Vandetanib</intervention_name>
    <description>300 mg as a once daily oral dose, from Day 1 until disease progression or unacceptable toxicity or consent withdrawal whichever occurs first</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Zactima</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZD6474, Vandetanib</intervention_name>
    <description>100 mg as a once daily oral dose, from Day 1 until disease progression or unacceptable toxicity or consent withdrawal whichever occurs first</description>
    <arm_group_label>B</arm_group_label>
    <other_name>Zactima</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>administered intravenously at 1000 mg/m2 over 30 minutes on Days 1 and 8 of each 21-day cycle up to 6 cycles or until disease progression or unacceptable toxicity or consent withdrawal whichever occurs first</description>
    <arm_group_label>B</arm_group_label>
    <arm_group_label>C</arm_group_label>
    <other_name>Gemzar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo matching ZD6474</intervention_name>
    <description>Placebo to match ZD6474 100 mg as a once daily oral dose, from Day 1 until disease progression or unacceptable toxicity or consent withdrawal whichever occurs first</description>
    <arm_group_label>C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically-confirmed advanced (unresectable or metastatic)
             biliary tract cancer (gallbladder cancer, cancer of the extrahepatic bile duct,
             intrahepatic cholangiocarcinoma and ampullary carcinoma)

          -  Patients must have measurable or evaluable but non-measurable disease

          -  Chemotherapy-naïve (prior chemotherapy in the adjuvant setting completed more than 3
             months before the trial entry is accepted).

          -  WHO performance status 0 to 2: patients must have a WHO PS ≤ 2

        Exclusion Criteria:

          -  Patients must not have received prior systemic therapy for advanced (unresectable or
             metastatic) disease; prior chemotherapy in the adjuvant setting within 3 months
             before the trial entry is accepted

          -  Inadequate end-organ function or Evidence of severe or uncontrolled systemic disease
             or any concurrent condition which in the Investigator's opinion makes it undesirable
             for the patient to participate in the trial or which would jeopardize compliance wit

          -  Significant cardiovascular event (e.g. myocardial infarction, superior vena cava
             [SVC] syndrome, New York Heart Association [NYHA] classification of heart disease ³2)
             within 3 months before entry, or presence of cardiac disease that in the opinion of

          -  History of arrhythmia or QTc with Bazett's correction unmeasurable or ≥ 480 msec on
             screening ECG
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Armando Santoro, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Istituto Clinico Humanitas - ROZZANO (MI) ITALY</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lorenza Rimassa, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Istituto Clinico Humanitas - ROZZANO (MI) ITALY</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter Langmuir, MD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brescia</city>
        <state>BS</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Firenze</city>
        <state>FI</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Genova</city>
        <state>GE</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Milano</city>
        <state>Mi</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Palermo</city>
        <state>PA</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Aviano</city>
        <state>PN</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Parma</city>
        <state>PR</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Reggio Emilia</city>
        <state>RE</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ancona</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Livorno</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pisa</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ravenna</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rho</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Wedge SR, Ogilvie DJ, Dukes M, Kendrew J, Chester R, Jackson JA, Boffey SJ, Valentine PJ, Curwen JO, Musgrove HL, Graham GA, Hughes GD, Thomas AP, Stokes ES, Curry B, Richmond GH, Wadsworth PF, Bigley AL, Hennequin LF. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res. 2002 Aug 15;62(16):4645-55.</citation>
    <PMID>12183421</PMID>
  </reference>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 27, 2013</lastchanged_date>
  <firstreceived_date>September 15, 2008</firstreceived_date>
  <firstreceived_results_date>September 27, 2013</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Intrahepatic</keyword>
  <keyword>Cholangiocarcinoma</keyword>
  <keyword>Vandetanib</keyword>
  <keyword>Zactima</keyword>
  <keyword>Advanced</keyword>
  <keyword>Biliary</keyword>
  <keyword>Tract</keyword>
  <keyword>Gallbladder</keyword>
  <keyword>Extrahepatic Bile Duct</keyword>
  <keyword>Intrahepatic Cholangiocarcinoma</keyword>
  <keyword>Ampullary Carcinoma</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Biliary Tract Neoplasms</mesh_term>
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Cholangiocarcinoma</mesh_term>
    <mesh_term>Gallbladder Neoplasms</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Gemcitabine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>180 subjects were screened at 19 sites and 174 were randomized</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Arm A Vandetanib 300 mg</title>
          <description>Vandetanib 300 mg as a once daily oral dose, from Day 1</description>
        </group>
        <group group_id="P2">
          <title>Arm B Vandetanib 100mg + Gemcitab</title>
          <description>Gemcitabine administered intravenously at 1000 mg/m2 over 30 minutes on Days 1 and 8 of each 21-day cycle up to plus Vandetanib 100 mg orally once-daily, from Day 1 (after 6 cycles, in the absence of disease progression or unacceptable toxicity, Investigators remain at liberty to continue Gemcitabine plus Vandetanib / Placebo or to continue Vandetanib / Placebo monotherapy)</description>
        </group>
        <group group_id="P3">
          <title>ARM C Placebo+ Gemcitabine</title>
          <description>Gemcitabine administered intravenously at 1000 mg/m2 over 30 minutes on Days 1 and 8 of each 21-day cycle up to 6 cycles plus Vandetanib 100 mg Matching Placebo orally once-daily, from Day 1 (after 6 cycles, in the absence of disease progression or unacceptable toxicity, Investigators remain at liberty to continue Gemcitabine plus Vandetanib / Placebo or to continue Vandetanib / Placebo monotherapy).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="59"/>
                <participants group_id="P2" count="59"/>
                <participants group_id="P3" count="56"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="59"/>
                <participants group_id="P2" count="59"/>
                <participants group_id="P3" count="56"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>other reason</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Objective progression of disease</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="35"/>
                <participants group_id="P3" count="35"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Patient screened 180 Patient Randomized 174 (1 never treated) Sceening failures 6 Patient Treated 173 (ITT=165 ; 8 excluded from ITT due to missing postbaseline assesment)</population>
      <group_list>
        <group group_id="B1">
          <title>Arm A Vandetanib 300 mg</title>
          <description>Vandetanib 300 mg as a once daily oral dose, from Day 1</description>
        </group>
        <group group_id="B2">
          <title>Arm B Vandetanib 100mg + Gemcitab</title>
          <description>Gemcitabine administered intravenously at 1000 mg/m2 over 30 minutes on Days 1 and 8 of each 21-day cycle up to plus Vandetanib 100 mg orally once-daily, from Day 1 (after 6 cycles, in the absence of disease progression or unacceptable toxicity, Investigators remain at liberty to continue Gemcitabine plus Vandetanib / Placebo or to continue Vandetanib / Placebo monotherapy)</description>
        </group>
        <group group_id="B3">
          <title>ARM C Placebo+ Gemcitabine</title>
          <description>Gemcitabine administered intravenously at 1000 mg/m2 over 30 minutes on Days 1 and 8 of each 21-day cycle up to 6 cycles plus Vandetanib 100 mg Matching Placebo orally once-daily, from Day 1 (after 6 cycles, in the absence of disease progression or unacceptable toxicity, Investigators remain at liberty to continue Gemcitabine plus Vandetanib / Placebo or to continue Vandetanib / Placebo monotherapy).</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="59"/>
                <measurement group_id="B2" value="58"/>
                <measurement group_id="B3" value="56"/>
                <measurement group_id="B4" value="173"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <description>Safety Population</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="62.39" spread="10.108"/>
                <measurement group_id="B2" value="64.41" spread="9.455"/>
                <measurement group_id="B3" value="63.95" spread="8.764"/>
                <measurement group_id="B4" value="63.57" spread="9.456"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <description>Safety Population</description>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="34"/>
                <measurement group_id="B2" value="27"/>
                <measurement group_id="B3" value="31"/>
                <measurement group_id="B4" value="92"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="25"/>
                <measurement group_id="B2" value="31"/>
                <measurement group_id="B3" value="25"/>
                <measurement group_id="B4" value="81"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression Free Survival</title>
        <description>PFS is calculated from the date of first dose of study medication until the date of objective progression or death (by any cause in the absence of progression). Patients who have not progressed or died at the time of statistical analysis will be censored at the time of their latest objective tumor assessment</description>
        <time_frame>up to 1032 days</time_frame>
        <safety_issue>No</safety_issue>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A Vandetanib 300 mg</title>
            <description>Vandetanib 300 mg as a once daily oral dose, from Day 1</description>
          </group>
          <group group_id="O2">
            <title>Arm B Vandetanib 100mg + Gemcitab</title>
            <description>Gemcitabine administered intravenously at 1000 mg/m2 over 30 minutes on Days 1 and 8 of each 21-day cycle up to plus Vandetanib 100 mg orally once-daily, from Day 1 (after 6 cycles, in the absence of disease progression or unacceptable toxicity, Investigators remain at liberty to continue Gemcitabine plus Vandetanib / Placebo or to continue Vandetanib / Placebo monotherapy)</description>
          </group>
          <group group_id="O3">
            <title>ARM C Placebo+ Gemcitabine</title>
            <description>Gemcitabine administered intravenously at 1000 mg/m2 over 30 minutes on Days 1 and 8 of each 21-day cycle up to 6 cycles plus Vandetanib 100 mg Matching Placebo orally once-daily, from Day 1 (after 6 cycles, in the absence of disease progression or unacceptable toxicity, Investigators remain at liberty to continue Gemcitabine plus Vandetanib / Placebo or to continue Vandetanib / Placebo monotherapy).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="56"/>
                  <measurement group_id="O2" value="57"/>
                  <measurement group_id="O3" value="52"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Progression Free Survival</title>
            <description>PFS is calculated from the date of first dose of study medication until the date of objective progression or death (by any cause in the absence of progression). Patients who have not progressed or died at the time of statistical analysis will be censored at the time of their latest objective tumor assessment</description>
            <units>days</units>
            <param>Median</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="105" lower_limit="72" upper_limit="155"/>
                  <measurement group_id="O2" value="114" lower_limit="91" upper_limit="193"/>
                  <measurement group_id="O3" value="148" lower_limit="72" upper_limit="225"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Objective Tumor Response Rate (CR+PR),</title>
        <description>ORR is the sum of patients with best overall complete or partial responses divided by the patients in the analysis</description>
        <time_frame>up to 1032 days</time_frame>
        <safety_issue>No</safety_issue>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A Vandetanib 300 mg</title>
            <description>Vandetanib 300 mg as a once daily oral dose, from Day 1</description>
          </group>
          <group group_id="O2">
            <title>Arm B Vandetanib 100mg + Gemcitab</title>
            <description>Gemcitabine administered intravenously at 1000 mg/m2 over 30 minutes on Days 1 and 8 of each 21-day cycle up to plus Vandetanib 100 mg orally once-daily, from Day 1 (after 6 cycles, in the absence of disease progression or unacceptable toxicity, Investigators remain at liberty to continue Gemcitabine plus Vandetanib / Placebo or to continue Vandetanib / Placebo monotherapy)</description>
          </group>
          <group group_id="O3">
            <title>ARM C Placebo+ Gemcitabine</title>
            <description>Gemcitabine administered intravenously at 1000 mg/m2 over 30 minutes on Days 1 and 8 of each 21-day cycle up to 6 cycles plus Vandetanib 100 mg Matching Placebo orally once-daily, from Day 1 (after 6 cycles, in the absence of disease progression or unacceptable toxicity, Investigators remain at liberty to continue Gemcitabine plus Vandetanib / Placebo or to continue Vandetanib / Placebo monotherapy).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="56"/>
                  <measurement group_id="O2" value="57"/>
                  <measurement group_id="O3" value="52"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Objective Tumor Response Rate (CR+PR),</title>
            <description>ORR is the sum of patients with best overall complete or partial responses divided by the patients in the analysis</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Objective Response = NO</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="54"/>
                  <measurement group_id="O2" value="46"/>
                  <measurement group_id="O3" value="45"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Objective Response = YES</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="11"/>
                  <measurement group_id="O3" value="7"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease Control Rate (CR+PR+SD)</title>
        <description>DCR is the sum of patients with a best overall CR, PR or SD (&gt;=8 weeks) by the patient in the analysis</description>
        <time_frame>up to 1032 days</time_frame>
        <safety_issue>No</safety_issue>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A Vandetanib 300 mg</title>
            <description>Vandetanib 300 mg as a once daily oral dose, from Day 1</description>
          </group>
          <group group_id="O2">
            <title>Arm B Vandetanib 100mg + Gemcitab</title>
            <description>Gemcitabine administered intravenously at 1000 mg/m2 over 30 minutes on Days 1 and 8 of each 21-day cycle up to plus Vandetanib 100 mg orally once-daily, from Day 1 (after 6 cycles, in the absence of disease progression or unacceptable toxicity, Investigators remain at liberty to continue Gemcitabine plus Vandetanib / Placebo or to continue Vandetanib / Placebo monotherapy)</description>
          </group>
          <group group_id="O3">
            <title>ARM C Placebo+ Gemcitabine</title>
            <description>Gemcitabine administered intravenously at 1000 mg/m2 over 30 minutes on Days 1 and 8 of each 21-day cycle up to 6 cycles plus Vandetanib 100 mg Matching Placebo orally once-daily, from Day 1 (after 6 cycles, in the absence of disease progression or unacceptable toxicity, Investigators remain at liberty to continue Gemcitabine plus Vandetanib / Placebo or to continue Vandetanib / Placebo monotherapy).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="56"/>
                  <measurement group_id="O2" value="57"/>
                  <measurement group_id="O3" value="52"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Disease Control Rate (CR+PR+SD)</title>
            <description>DCR is the sum of patients with a best overall CR, PR or SD (&gt;=8 weeks) by the patient in the analysis</description>
            <units>Partecipants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Disease control rate = NO</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="42"/>
                  <measurement group_id="O2" value="40"/>
                  <measurement group_id="O3" value="32"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Disease control rate = YES</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="14"/>
                  <measurement group_id="O2" value="17"/>
                  <measurement group_id="O3" value="20"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response (DOR)</title>
        <description>DOR is defined from the date of first documentation of response until date of PD or death</description>
        <time_frame>up to 1032 days</time_frame>
        <safety_issue>No</safety_issue>
        <population>ITT (best response of CR or PR only)</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A Vandetanib 300 mg</title>
            <description>Vandetanib 300 mg as a once daily oral dose, from Day 1</description>
          </group>
          <group group_id="O2">
            <title>Arm B Vandetanib 100mg + Gemcitab</title>
            <description>Gemcitabine administered intravenously at 1000 mg/m2 over 30 minutes on Days 1 and 8 of each 21-day cycle up to plus Vandetanib 100 mg orally once-daily, from Day 1 (after 6 cycles, in the absence of disease progression or unacceptable toxicity, Investigators remain at liberty to continue Gemcitabine plus Vandetanib / Placebo or to continue Vandetanib / Placebo monotherapy)</description>
          </group>
          <group group_id="O3">
            <title>ARM C Placebo+ Gemcitabine</title>
            <description>Gemcitabine administered intravenously at 1000 mg/m2 over 30 minutes on Days 1 and 8 of each 21-day cycle up to 6 cycles plus Vandetanib 100 mg Matching Placebo orally once-daily, from Day 1 (after 6 cycles, in the absence of disease progression or unacceptable toxicity, Investigators remain at liberty to continue Gemcitabine plus Vandetanib / Placebo or to continue Vandetanib / Placebo monotherapy).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="11"/>
                  <measurement group_id="O3" value="7"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Duration of Response (DOR)</title>
            <description>DOR is defined from the date of first documentation of response until date of PD or death</description>
            <units>Days</units>
            <param>Median</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="277" lower_limit="267" upper_limit="286"/>
                  <measurement group_id="O2" value="179" lower_limit="85" upper_limit="369"/>
                  <measurement group_id="O3" value="127" lower_limit="85" upper_limit="152"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survivall</title>
        <description>OS is defined from the date of randomization to death</description>
        <time_frame>up to 1032 days</time_frame>
        <safety_issue>No</safety_issue>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A Vandetanib 300 mg</title>
            <description>Vandetanib 300 mg as a once daily oral dose, from Day 1</description>
          </group>
          <group group_id="O2">
            <title>Arm B Vandetanib 100mg + Gemcitab</title>
            <description>Gemcitabine administered intravenously at 1000 mg/m2 over 30 minutes on Days 1 and 8 of each 21-day cycle up to plus Vandetanib 100 mg orally once-daily, from Day 1 (after 6 cycles, in the absence of disease progression or unacceptable toxicity, Investigators remain at liberty to continue Gemcitabine plus Vandetanib / Placebo or to continue Vandetanib / Placebo monotherapy)</description>
          </group>
          <group group_id="O3">
            <title>ARM C Placebo+ Gemcitabine</title>
            <description>Gemcitabine administered intravenously at 1000 mg/m2 over 30 minutes on Days 1 and 8 of each 21-day cycle up to 6 cycles plus Vandetanib 100 mg Matching Placebo orally once-daily, from Day 1 (after 6 cycles, in the absence of disease progression or unacceptable toxicity, Investigators remain at liberty to continue Gemcitabine plus Vandetanib / Placebo or to continue Vandetanib / Placebo monotherapy).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="56"/>
                  <measurement group_id="O2" value="57"/>
                  <measurement group_id="O3" value="52"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Overall Survivall</title>
            <description>OS is defined from the date of randomization to death</description>
            <units>Days</units>
            <param>Median</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="228" lower_limit="190" upper_limit="364"/>
                  <measurement group_id="O2" value="284" lower_limit="213" upper_limit="359"/>
                  <measurement group_id="O3" value="307" lower_limit="254" upper_limit="523"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Arm A Vandetanib 300 mg</title>
          <description>Vandetanib 300 mg as a once daily oral dose, from Day 1</description>
        </group>
        <group group_id="E2">
          <title>Arm B Vandetanib 100mg + Gemcitab</title>
          <description>Gemcitabine administered intravenously at 1000 mg/m2 over 30 minutes on Days 1 and 8 of each 21-day cycle up to plus Vandetanib 100 mg orally once-daily, from Day 1 (after 6 cycles, in the absence of disease progression or unacceptable toxicity, Investigators remain at liberty to continue Gemcitabine plus Vandetanib / Placebo or to continue Vandetanib / Placebo monotherapy)</description>
        </group>
        <group group_id="E3">
          <title>ARM C Placebo+ Gemcitabine</title>
          <description>Gemcitabine administered intravenously at 1000 mg/m2 over 30 minutes on Days 1 and 8 of each 21-day cycle up to 6 cycles plus Vandetanib 100 mg Matching Placebo orally once-daily, from Day 1 (after 6 cycles, in the absence of disease progression or unacceptable toxicity, Investigators remain at liberty to continue Gemcitabine plus Vandetanib / Placebo or to continue Vandetanib / Placebo monotherapy).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MeDRA 15.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA 15.0">Disseminated Intravascular</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title vocab="MeDra">Pancytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title vocab="MeDra">Thrombocytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA 15.0">Acute Myocardial Infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 15.0">Cardiac Failure Acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 15.0">Torsade de Pointes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 15.0">Ascites</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 15.0">Duodenal Obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 15.0">Intestinal Obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 15.0">Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 15.0">Vomiting</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Condition Aggravated</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>General Physical Health Deterioration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Hepatic Failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Cholangites</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Hepatic Failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Hyperbilirubineamia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood Bilirubin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Blood Bilirubin increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Electrocardiogram Repolarisation Abnormaly</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Cachexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Metabolic Acidosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Oliguria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Renal Failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Renal Failure Acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Pulmonary Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA 15.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="50" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="20" subjects_affected="10" subjects_at_risk="58"/>
                <counts group_id="E3" events="18" subjects_affected="7" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title vocab="MeDRA 15.0">Anemia macrocytic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title vocab="MeDRA 15.0">Autoimmune thrombocytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title vocab="MeDRA 15.0">Dessemintaed Intracascula Coagulation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title vocab="MeDRA 15.0">Hyperbilirubineamia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title vocab="MeDRA 15.0">Iron deficency anemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title vocab="MeDRA 15.0">Leukcytosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title vocab="MeDRA 15.0">Leukopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="6" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E3" events="17" subjects_affected="6" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title vocab="MeDRA 15.0">Pancytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title vocab="MeDRA 15.0">Platelet production decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title vocab="MeDRA 15.0">Thrombocytopenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="58"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Thrombocytosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title vocab="MeDRA 15.0">White blood cell disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title vocab="MeDRA 15.0">Neutropenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="15" subjects_affected="7" subjects_at_risk="58"/>
                <counts group_id="E3" events="28" subjects_affected="10" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Myocardial Infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title vocab="MeDRA 15.0">Arrhytmia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title vocab="MeDRA 15.0">Atrial Fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title vocab="MeDRA 15.0">Bundle branch block</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title vocab="MeDRA 15.0">Bundle Branch block right</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title vocab="MeDRA 15.0">Cardiac Failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title vocab="MeDRA 15.0">Cardiac Failure Acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title vocab="MeDRA 15.0">Extrasystoles</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title vocab="MeDRA 15.0">Oedema peripheral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title vocab="MeDRA 15.0">Sinus tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title vocab="MeDRA 15.0">Tachycardia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title vocab="MeDRA 15.0">Torsade de pointes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MeDRA 15.0">Vertigo</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MeDRA 15.0">Diabete Mellitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title vocab="MeDRA 15.0">Hyperglycamia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MeDRA 15.0">Conjunctival hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title vocab="MeDRA 15.0">Eye pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title vocab="MeDRA 15.0">Ocular icterus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title vocab="MeDRA 15.0">Periorbital Oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Distension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title vocab="MeDRA 15.0">Abdominal mass</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title vocab="MeDRA 15.0">Abdominal pain</sub_title>
                <counts group_id="E1" events="16" subjects_affected="15" subjects_at_risk="59"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="58"/>
                <counts group_id="E3" events="17" subjects_affected="14" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title vocab="MeDRA 15.0">Abdominal Pain upper</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="58"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title vocab="MeDRA 15.0">Aborectal discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title vocab="MeDRA 15.0">Ascites</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="59"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title vocab="MeDRA 15.0">Constipation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title vocab="MeDRA 15.0">Diarrhoea</sub_title>
                <counts group_id="E1" events="32" subjects_affected="15" subjects_at_risk="59"/>
                <counts group_id="E2" events="13" subjects_affected="6" subjects_at_risk="58"/>
                <counts group_id="E3" events="10" subjects_affected="8" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title vocab="MeDRA 15.0">Dry mouth</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title vocab="MeDRA 15.0">Duodenal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title vocab="MeDRA 15.0">Dysgeusia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title vocab="MeDRA 15.0">Dyspepsia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="4" subjects_affected="2" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title vocab="MeDRA 15.0">Dyshagia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title vocab="MeDRA 15.0">Gastrointestinal toxicity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title vocab="MeDRA 15.0">Gastroesophageal reflux disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title vocab="MeDRA 15.0">Gingivitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title vocab="MeDRA 15.0">Haemorrhoids</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title vocab="MeDRA 15.0">Hiccups</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title vocab="MeDRA 15.0">Intestinal Obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title vocab="MeDRA 15.0">Nausea</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="59"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="58"/>
                <counts group_id="E3" events="29" subjects_affected="17" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title vocab="MeDRA 15.0">Oral Mucosal erythema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title vocab="MeDRA 15.0">Pelvic Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title vocab="MeDRA 15.0">proctalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title vocab="MeDRA 15.0">Proctitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title vocab="MeDRA 15.0">Stomatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title vocab="MeDRA 15.0">Vomiting</sub_title>
                <counts group_id="E1" events="11" subjects_affected="8" subjects_at_risk="59"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="58"/>
                <counts group_id="E3" events="21" subjects_affected="9" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <description>General disorders and administration site conditions</description>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="59"/>
                <counts group_id="E2" events="17" subjects_affected="14" subjects_at_risk="58"/>
                <counts group_id="E3" events="20" subjects_affected="15" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title vocab="MeDRA 15.0">Chest Pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title vocab="MeDRA 15.0">Condition aggravated</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title vocab="MeDRA 15.0">Fatigue</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="59"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="58"/>
                <counts group_id="E3" events="11" subjects_affected="8" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title vocab="MeDRA 15.0">General physical health deterioration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title vocab="MeDRA 15.0">Gravitational oedema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title vocab="MeDRA 15.0">Hyperhidrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title vocab="MeDRA 15.0">Hyperpyrexia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title vocab="MeDra 15.0">Malaise</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title vocab="MeDra 15.0">Mucosal Inflammation</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="59"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title vocab="MeDra 15.0">Multi organ failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title vocab="MeDra 15.0">Oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title vocab="MeDra 15.0">Oedema Peripheral</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E2" events="9" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E3" events="3" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title vocab="MedDra 15.0">Pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title vocab="MedDra 15.0">Pyrexia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="59"/>
                <counts group_id="E2" events="22" subjects_affected="14" subjects_at_risk="58"/>
                <counts group_id="E3" events="22" subjects_affected="14" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Hepatic Failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Bile Duct Obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Cholangites</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Hepatic Failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="4" subjects_at_risk="59"/>
                <counts group_id="E2" events="10" subjects_affected="5" subjects_at_risk="58"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Hypertrasaminasaemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Liver injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title vocab="MeDRA 15.0">Hepatic pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Contrast media allergy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bacterial Rhinitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Cystis escherichia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Hepatobiliary infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Oral Herpes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Skin Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Tooth abcess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Spinal Fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Aspartate aminotranferase</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Asparteate amonotranferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Blood Bilirubin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Blood Bilirubin increased</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Blood creatine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Blood glucose decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Blood lactate dehdrogenase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Blood potassium increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Blood urea increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Electrocardiogram QT prolonged</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Electrocardiogram T wave inversion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Electrocardiogram abnormal</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Electrocardiogram repolarisation abnormaly</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Gamma -glumayltransferase</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="5" subjects_affected="3" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>International normalised ratio increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Platelet count increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Transaminase increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title vocab="MeDRA 15.0">Urine colour abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Cachexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="59"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="58"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Deydratation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Hypercalcemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Hypercreatininaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Metabolic Acidosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Bone Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Hypercreatinaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Intervertebral disc degeneration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Neck Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Pain in the extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Spinal Compression Fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title vocab="MedRa 15.0">Metastic Neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title vocab="MedRa 15.0">Metastic Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title vocab="MedRa 15.0">Tumor associated fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Agitated Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Clonus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Dysarthria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Head Discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Hypogeusia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Neuralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title vocab="Medra 15.0">Depression</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title vocab="Medra 15.0">Insomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title vocab="Medra 15.0">Panic disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title vocab="Medra 15.0">Sleep disorder due to general medical condition , insomnia type</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Bladder hypertrophy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title vocab="Medra 15.0">Dysuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title vocab="Medra 15.0">Haematuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title vocab="Medra 15.0">Hypercreatininaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title vocab="Medra 15.0">Oliguria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title vocab="Medra 15.0">Proteinuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E3" events="5" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title vocab="Medra 15.0">Renal failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title vocab="Medra 15.0">Renal failure acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title vocab="Medra 15.0">Strangury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title vocab="Medra 15.0">Urinary incontinence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title vocab="Medra 15.0">Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Dysponea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Dysponea exertional</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" events="8" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Drug Eruption</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Dry Skin</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="13" subjects_affected="5" subjects_at_risk="59"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="58"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Exfoliative rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Face Oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Onycholysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Palmar-plantar erythrodysaesthesia syndrome</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Pruritus generalised</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="21" subjects_affected="15" subjects_at_risk="59"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="58"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Rash erythematous</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Skin Toxicity</sub_title>
                <counts group_id="E1" events="6" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep Vein thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Diastolic hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Essential hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="17" subjects_affected="14" subjects_at_risk="59"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="58"/>
                <counts group_id="E3" events="6" subjects_affected="4" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Systolic hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Venous insufficiency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Venous thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Venous thrombosis limb</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ian Thomas</name_or_title>
      <organization>AstraZeneca</organization>
      <phone>+44 1625 515571</phone>
      <email>ClinicalTrialTransparency.@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
